Rowena Santos, MD
Internal Medicine · Saint Louis, MONPI 1700942224
Payments from drug & device makers
Across 168 payments — averaging $94.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$13K
- AbbVie$571
- AstraZeneca$345
- Novo Nordisk$337
- Merz North America, Inc.$250
- Pfizer$214
- plus $1K from 16 others
What the payments were for
- Speaking & faculty fees$12,96081%
- Food & beverage$2,94519%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 13 | $13,107 |
| AbbVie | 22 | $571 |
| AstraZeneca | 17 | $345 |
| Novo Nordisk | 27 | $337 |
| Merz North America, Inc. | 1 | $250 |
| Pfizer | 15 | $214 |
| Johnson & Johnson | 11 | $173 |
| Novartis | 14 | $156 |
| GSK | 9 | $140 |
| Sanofi-aventis U.S. LLC | 7 | $127 |
| Lilly USA, LLC | 5 | $89 |
| E.r. Squibb & Sons, L.L.C. | 6 | $84 |
| Amarin Pharma, Inc. | 4 | $57 |
| Astellas Pharma US Inc | 3 | $45 |
| Boehringer Ingelheim | 3 | $41 |
| Abbott | 2 | $40 |
| Merck | 3 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $37 |
| Circassia Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,905 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 109 | $133,471 |
| EliquisApixaban | 84 | $69,680 |
| MounjaroTirzepatide | 51 | $58,192 |
| JardianceEmpagliflozin | 26 | $31,450 |
| TrulicityDulaglutide | 15 | $25,378 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 55 | $15,231 |
| FarxigaDapagliflozin Propanediol | 12 | $15,166 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $15,073 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $14,380 |
| XareltoRivaroxaban | 17 | $14,000 |
| Spiriva RespimatTiotropium Bromide | 27 | $13,824 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $12,601 |
| JanuviaSitagliptin Phosphate | 13 | $11,488 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $10,399 |
| MyrbetriqMirabegron | 11 | $8,405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $337 | $133,471109 claims |
| Lilly USA, LLCMounjaro, Trulicity | $89 | $83,57066 claims |
| PfizerEliquis | $214 | $69,68084 claims |
| GSKArexvy, Breo Ellipta, Trelegy Ellipta, Anoro Ellipta | $140 | $57,286133 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $41 | $45,27453 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $345 | $25,56427 claims |
| Johnson & JohnsonXarelto | $173 | $14,00017 claims |
| MerckJanuvia | $37 | $11,48813 claims |
| Astellas Pharma US IncMyrbetriq | $45 | $8,40511 claims |
| AbbVieSynthroid, Lumigan | $571 | $5,77842 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Saint Louis
- Michael ReschakSaint Louis$3.1M
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Hany SalamaSaint Louis$279K
- Lauren LevineSaint Louis$264K
- Brij VaidSaint Louis$213K
- Vinay KamatSaint Louis$191K
- Tracy NorfleetSaint Louis$132K
- Paul OlivoSaint Louis$98K
- Priyanka RavalSaint Louis$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.